<DOC>
	<DOCNO>NCT01075126</DOCNO>
	<brief_summary>It hypothesize Depakote well tolerate lithium treat African Americans bipolar disorder .</brief_summary>
	<brief_title>Safety Study Depakote Versus Lithium African Americans With Bipolar Disorder</brief_title>
	<detailed_description>This 14 week randomize open study 50 inpatient outpatient bipolar I r II . African American subject receive lithium depakote ER . Measures make psychopathology , report side effect , study completers . Measures also make RBC/plasma lithium determine level well predictive lithium tolerability .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Male female Females must use contraceptive Understand sing inform consent Meet criterion DSM IV bipolar I II Must receive treatment depakote lithium least 4 week Must use illicit substance 48 hour study Not takin g lithium valproate time screen Alcohol intoxicate use drug abuse cannibis Presence psychotic feature Participation clinical trail within 1 month study Female subject pregnant nursing Serious unstable medical psychiatric illness Uncorrected hypothyroidism hyperthyroidism Seizures without clear resolve etiology Hypersensitivity intolerance lithium valproic acid Treatment injectable depot neuroleptic le one dosing interval Treatment reversible MAOI , guanethidine , guanadrel within week study Treatment fluoxetine within 8 weekS study treatment clozapine ECT 3 month prior study current diagnosis schizophrenia psychotic disorder judge serious suicidal risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>bipolar affective disorder</keyword>
	<keyword>African American</keyword>
	<keyword>antimanic</keyword>
	<keyword>lithium</keyword>
	<keyword>depakote</keyword>
</DOC>